Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | NPC1 | O15118 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30493009 | 0.85 | APP (0.54) | RAB9AMAPTNPC1SMN1; SMN2TP53 | |
| SCHEMBL22860334 | 0.84 | SMN1; SMN2 (0.59) | RAB9AMAPTNPC1SMN1; SMN2TP53 | |
| SCHEMBL29194021 | 0.82 | APP (0.57) | RAB9AMAPTNPC1SMN1; SMN2TP53 | |
| SCHEMBL74296 | 0.82 | RAB9A (1.00) | RAB9AMAPTNPC1SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL21954211 | 0.81 | MAPT (0.50) | RAB9AMAPTNPC1SMN1; SMN2TP53 | |
| SCHEMBL3054921 | 0.80 | APP (0.49) | RAB9AMAPTNPC1SMN1; SMN2TP53 | |
| SCHEMBL25809876 | 0.78 | APP (0.50) | RAB9AMAPTNPC1SMN1; SMN2TP53 | |
| SCHEMBL30101607 | 0.76 | ILK (0.64) | RAB9AMAPTNPC1SMN1; SMN2DRD2 | |
| SCHEMBL28849842 | 0.76 | ILK (0.64) | RAB9AMAPTNPC1SMN1; SMN2DRD2 | |
| SCHEMBL12272999 | 0.75 | APP (0.47) | RAB9AMAPTNPC1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4545525-A1 | NOVEL COMPOUND AND USE THEREOF FOR TREATMENT OF AUTOIMMUNE DISEASES | Parenchyma Biotech Inc. (KR) | 2025-04-30 | — | — | EP | disclosed |
| US-12187717-B2 | Compound and use thereof in treating autoimmune diseases | PARENCHYMA BIOTECH INC. (KR) | 2025-01-07 | — | — | US | disclosed |
| CN-119233975-A | Novel compounds and their use for the treatment of autoimmune diseases | 帕连齐玛生物技术株式会社 | 2024-12-31 | — | — | CN | disclosed |
| WO-2023249228-A1 | NOVEL COMPOUND AND USE THEREOF FOR TREATMENT OF AUTOIMMUNE DISEASES | 파렌키마바이오텍 주식회사 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249228-A1 | NOVEL COMPOUND AND USE THEREOF FOR TREATMENT OF AUTOIMMUNE DISEASES | 파렌키마바이오텍 주식회사 | 2023-12-28 | — | — | WO | disclosed |
| US-20230406848-A1 | COMPOUND AND USE THEREOF IN TREATING AUTOIMMUNE DISEASES | PARENCHYMA BIOTECH INC. (KR) | 2023-12-21 | — | — | US | disclosed |
| US-11807637-B1 | Compound and use thereof in treating autoimmune diseases | PARENCHYMA BIOTECH INC. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-11807637-B1 | Compound and use thereof in treating autoimmune diseases | PARENCHYMA BIOTECH INC. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-11807637-B1 | Compound and use thereof in treating autoimmune diseases | PARENCHYMA BIOTECH INC. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-10005769-B2 | 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors | 4SC AG (DE) | 2018-06-26 | — | — | US | disclosed |
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100048583-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048574-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100004258-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-01-07 | — | — | US | disclosed |
| CN-101448843-A | Imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCES CORP (US) | 2009-06-03 | — | — | CN | disclosed |
| EP-2001892-A2 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | Ambit Biosciences Corporation (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20080261971-A1 | Novel Heterocyclic Nf-Kb Inhibitors | 4SC AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007109120-A2 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20060247253-A1 | Novel heterocyclic NF-kB inhibitors | 4 SC AG (DE) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKB2, NFKBIA, NFRKB | RAB9A 3958/4885MAPT 4818/4885NPC1 2626/4885 |
| US-20100048574-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | NFKBIA, IKBKB, NFKB2 | RAB9A 2004/4885MAPT 2332/4885NPC1 1036/4885 |
| US-20230406848-A1 | COMPOUND AND USE THEREOF IN TREATING AUTOIMMUNE DISEASES | GSTA1, BRCA1, BACH1 | RAB9A 1392/4885MAPT 1900/4885NPC1 1483/4885 |
| US-20060247253-A1 | Novel heterocyclic NF-kB inhibitors | NFKBIA, NFRKB, NFKB2 | RAB9A 3322/4885MAPT 4665/4885NPC1 2164/4885 |
| US-20100048583-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKBIA, NFKB2, NFRKB | RAB9A 3857/4885MAPT 4584/4885NPC1 2249/4885 |
| US-10005769-B2 | 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors | DYRK2, DYRK1B, DYRK1A | RAB9A 1851/4885MAPT 3014/4885NPC1 4390/4885 |
| US-12187717-B2 | Compound and use thereof in treating autoimmune diseases | GSTA1, BRCA1, BACH1 | RAB9A 1392/4885MAPT 1900/4885NPC1 1483/4885 |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | GRK2, GRK3, BLK | RAB9A 3007/4885MAPT 1520/4885NPC1 3817/4885 |
| US-11807637-B1 | Compound and use thereof in treating autoimmune diseases | GSTA1, BRCA1, BACH1 | RAB9A 1392/4885MAPT 1900/4885NPC1 1483/4885 |
| US-20080261971-A1 | Novel Heterocyclic Nf-Kb Inhibitors | NFKBIA, NFKB2, NFRKB | RAB9A 3984/4885MAPT 4540/4885NPC1 2327/4885 |
| US-20100004258-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKBIA, IKBKB, NFKB2 | RAB9A 1824/4885MAPT 2457/4885NPC1 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.